Specialty Pharma Journal Specialty, Precision & Technology
ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment …
Tag Archives: Ampion
December, 2017
April, 2015
-
20 April
Ampio Pharmaceuticals’ Lead Osteoarthritis Candidate Fails Late-Stage Study
Ampio Pharmaceuticals Inc. announced Monday that its lead drug for osteoarthritis failed its late-stage study. The news caused the biotech’s shares to plunge nearly 70 percent in early trading, the lowest level in two and a half years. Ampio said that in the multiple injection Phase III STRIDE study, AP008 …